Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy
H Nagase, M Suzukawa, K Oishi… - Allergology …, 2023 - jstage.jst.go.jp
abstract Biologics have been a key component of severe asthma treatment, and there are
currently biologics available that target IgE, IL-5, IL-4/IL-13, and TSLP. Randomized …
currently biologics available that target IgE, IL-5, IL-4/IL-13, and TSLP. Randomized …
Oral corticosteroids dependence and biologic drugs in severe asthma: myths or facts? A systematic review of real-world evidence
L Calzetta, M Aiello, A Frizzelli, G Bertorelli… - International Journal of …, 2021 - mdpi.com
Airway inflammation represents an important characteristic in asthma, modulating airflow
limitation and symptom control, and triggering the risk of asthma exacerbation. Thus …
limitation and symptom control, and triggering the risk of asthma exacerbation. Thus …
Difficult-to-treat asthma management in school-age children
The World Health Organization divides severe asthma into three categories: untreated
severe asthma; difficult-to-treat severe asthma; and severe, therapy-resistant asthma. The …
severe asthma; difficult-to-treat severe asthma; and severe, therapy-resistant asthma. The …
Long-term safety, durability of response, cessation and switching of biologics
A Mohan, AY Qiu, N Lugogo - Current Opinion in Pulmonary …, 2024 - journals.lww.com
Biologics are safe and effective long-term therapies for the management of asthma.
Discontinuation must be carefully considered and if possible avoided. Reasons for …
Discontinuation must be carefully considered and if possible avoided. Reasons for …
[PDF][PDF] Biological therapy management from the initial selection of biologics to switching between biologics in severe asthma.
The aim of this review is to elaborate the management of biologic therapy from initial
selection to switching biologics in severe asthma. A nonsystematic review was performed for …
selection to switching biologics in severe asthma. A nonsystematic review was performed for …
Eosinophil to lymphocyte ratio may predict OCS reduction and change in quality of life (AQLQ) resulting from asthma biological treatment
O Branicka, R Gawlik, J Glück - Immunopharmacology and …, 2024 - Taylor & Francis
Objectives Simple clinical parameters that could be helpful in choice of monoclonal
antibodies and prediction of their effectiveness are being sought. The aim was to assess if …
antibodies and prediction of their effectiveness are being sought. The aim was to assess if …
Application of Omalizumab Combined with Enteral Nutrition in Treating Severe Allergic Asthma.
L Zhong, Y Wang, X Fu… - Current Topics in …, 2024 - search.ebscohost.com
To investigate the influence of omalizumab combined with enteral nutrition in treating severe
allergic asthma, 102 patients in our hospital from May 2020 to May 2023 were …
allergic asthma, 102 patients in our hospital from May 2020 to May 2023 were …
[HTML][HTML] Biological therapy management from the initial selection of biologics to switching between biologics in severe asthma
İY Gülden, GP Çetin, B Arslan, S Şeker… - Tuberculosis and …, 2023 - ncbi.nlm.nih.gov
The aim of this review is to elaborate the management of biologic therapy from initial
selection to switching biologics in severe asthma. A nonsystematic review was performed for …
selection to switching biologics in severe asthma. A nonsystematic review was performed for …
Zasady postępowania u chorych z rozpoznaniem astmy ciężkiej leczonych glikokortykosteroidami systemowymi–zalecenia ekspertów dotyczące redukcji dawek i …
A Kucharczyk, L Bednarek-Papierska… - … -Polish Journal of …, 2022 - publicum.umed.lodz.pl
Astma to jedno z najczęstszych schorzeń przewlekłych. Dotyczy ponad 340 milionów ludzi
na świecie, przy czym w dalszym ciągu, pomimo szerokiego dostępu do nowoczesnych …
na świecie, przy czym w dalszym ciągu, pomimo szerokiego dostępu do nowoczesnych …
Principles of management of severe asthma patients treated with systemic glucocorticosteroids–Experts' recommendations on dose reduction and discontinuation of …
A Kucharczyk, L Bednarek-Papierska, A Barczyk… - … Polska-Polish Journal of … - termedia.pl
According to GINA guidelines chronic therapy with oral glucocorticosteroids in patients with
severe asthma must be limited to those who have been excluded from biological therapies …
severe asthma must be limited to those who have been excluded from biological therapies …